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COMPOUNDS

ABSTRACT

Generation of Lithium Cyclopentadienide
Combined 0.569 mL cyclopentadiene, 2.78 mL of butyl-lithium,
and 50 mL diethyl ether with stir bar into a 100 mL Schlenk flask
under argon. The reaction was stirred while in an ice bath for a
few minutes as the butyl-lithium was added via syringe needle.
The resulting mixture was stirred until reagents were added.

The synthesis of a variety of symmetric and asymmetric
hydroxyfulvenes was attempted via reaction of lithium
cyclopentadienide with acyl halides or esters. The purification and
analysis of the products via Hydrogen Nuclear Magnetic
Resonance (NMR) will be presented. Further experimentation
with hydroxy fulvenes will potentially form precursors to
compounds structurally similar to the Non-Steroidal AntiInflammatory Drug (NSAID) CELEBREX (celecoxib). A series of
potential analogous precursors in the form of alpha-beta
unsaturated ketones have been developed. The conversion of these
precursors into pyridazine compounds will be attempted in the
future. After oxidation of the pyrazoline compounds, they could
potentially have biological activity by acting through
CycloOxygense-2 (COX-2) in the same manner to CELEBREX.

INTRODUCTION
The broader objective of this research was to produce viable, or
better, analogs for the prescription drug CELEBREX.
CELEBREX is in the NSAID class of medications. NSAIDs are
used to inhibit COX-2 (CycloOXygenase-2), which is a promoter
of inflammation. CELEBREX is a unique compound as it does not
inhibit COX-1 as other NSAIDs do. Other NSAIDs prevent the
activity of COX-1, which ultimately prevents the stomach from
producing enough of a mucus coating to protect it from its
digestive acids; this can lead to ulcers in long term use. Celecoxib
is selective for COX-2 due to sterics. Celecoxib’s relatively large
structure fits into the pocket in the channel for COX-2. COX-1
does not have this channel, therefore, celecoxib cannot fit. This is
due to the two enzymes being isoforms, which means that the
channels share the same chemical structure, but differ in spatial
orientation. Figures 1 and 2 below depict reaction schemes for the
generation of Cyclopentadienide from Dicyclopentadiene and
generic acylation and formation of hydroxyfulvene product.

MATERIALS & METHODS

4-(1-p-tolyl-4-(trifluoromethyl)-2Hcyclopenta[d]pyridazine-2-yl)benzenesulfonamide
(Proposed CELEBREX Analog)

2-Furoyl Chloride

Propionyl Chloride

4-Fluorobenzoyl Chloride

Ethyl Trifluoroacetate

4-Chlorobenzoyl Chloride

Dicyclopentadiene

Generation of Substituted Hydroxyfulvenes
Added 3 mmol equivalents of 2 reagents (such as m-toluoyl
chloride and 4-fluorobenzoyl chloride), and ~8-9 mL ether to 25
mL round bottom flask. The mixture was added to 2 mmol
equivalents of lithium cyclopentadienide in the reaction flask from
previous generation. After warming to room temperature, the
mixture stirred overnight. An acid workup was performed using
HCl, excess water was removed using a desiccant, and leftover
ether was evaporated off using a rotavapor apparatus.

RESULTS
Early trials prepared using solid lithium cyclopentadienide were shown
to have much smaller yields as the solid form readily reacts in normal
atmosphere, thus producing an unreactive byproduct. This is evident by
the presence of carboxylic acid derivatives of the acyl halide reagents
used. Lithium Cyclopentadienide reactions, from distillation of
dicyclopentadiene and butyl lithium, proved much more reactive and
trials using this starting material produced mixtures of the three
possible hydroxyfulvene derivatives shown in H1-NMR analysis.

PROPOSED REACTION SCHEME
Reaction mechanism for the generation of lithium cyclopentadienide via Retro-Diels–Alder
reaction (Figure 1). Subsequently reacted with varying combinations of acyl halide reagents
in a 3:1:1 ratio, or 3:2 if symmetrical hydroxyfulvene formation (Figure 2).

DISCUSSION
There has been modest success with these procedures in regard to
H-NMR and Thin-Layer Chromatography (TLC). When analyzing
the hydroxyfulvene compounds with Nuclear Magnetic Imaging
(H-NMR), a reaction was deemed successful at minimum if one
robust peak was present between 18 and 20 ppm, and if the peaks
for an aromatic group and starting compound exclusive peaks had
appeared (between 7 and 9 ppm). Several compounds were
deemed to have potential, but required further investigation. This
was achieved through separation via TLC using silica plates and
varying mixtures of mobile phases, although it was found that a
mixture of pentane and diethyl ether worked best. To further
separate compounds, column chromatography was used, however
there was little separation with this method versus the TLC.

Figure 1. Formation of Cyclopentadienide.

Figure 3. H-NMR in CDCl3 at 90 MHz
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